Cargando…

Asthma-related hospitalizations after implementing SABA-free asthma management with a maintenance and anti-inflammatory reliever regimen

Overreliance on short-acting β(2)-agonists (SABA) has been a common feature of asthma management globally for at least 30 years. However, given the evidence against the long-term use of SABA, including potentially increased risk of exacerbations, emergency room visits, overall healthcare resource ut...

Descripción completa

Detalles Bibliográficos
Autores principales: Nannini, L. J., Neumayer, N. S., Brandan, N., Fernández, O. M., Flores, D. M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9361757/
https://www.ncbi.nlm.nih.gov/pubmed/35959199
http://dx.doi.org/10.1080/20018525.2022.2110706
_version_ 1784764593742020608
author Nannini, L. J.
Neumayer, N. S.
Brandan, N.
Fernández, O. M.
Flores, D. M.
author_facet Nannini, L. J.
Neumayer, N. S.
Brandan, N.
Fernández, O. M.
Flores, D. M.
author_sort Nannini, L. J.
collection PubMed
description Overreliance on short-acting β(2)-agonists (SABA) has been a common feature of asthma management globally for at least 30 years. However, given the evidence against the long-term use of SABA, including potentially increased risk of exacerbations, emergency room visits, overall healthcare resource utilization, and mortality, the latest Global Initiative for Asthma report no longer recommends SABA only therapy. Since 2014, we implemented an ICS-containing reliever strategy at our asthma center at the G Baigorria Hospital in Argentina; we only administered budesonide/formoterol via a single inhaler device across the spectrum of asthma severity and completely eliminated the use of SABA therapy. In this article, we compare hospitalization data from our center, previously reported in the EAGLE study (when inhaled corticosteroids plus as-needed SABA was administered) for the years 1999 and 2004 with data from 2017 to 2018 (when budesonide/formoterol in a single inhaler device was administered as maintenance and/or anti-inflammatory reliever therapy [MART/AIR] without any SABA) from our center, to assess the impact of two distinct asthma management strategies on asthma-related hospitalizations. MART/AIR regimens in our SABA-free center reduced asthma hospitalizations from 9 (1999 and 2004) to 1 (2017 and 2018) (Fisher’s exact test, p = 0.031; odds ratio = 0.11; 95% confidence interval [CI] = 0.013–0.98); the hospitalization rate was reduced by 92% (1.47% in 1999 and 2004 to 0.12% in 2017 and 2018). Our data provide preliminary real-world evidence that MART/AIR with budesonide/formoterol simultaneously with SABA elimination across asthma severities is an effective asthma management strategy for reducing asthma-related hospitalizations.
format Online
Article
Text
id pubmed-9361757
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Taylor & Francis
record_format MEDLINE/PubMed
spelling pubmed-93617572022-08-10 Asthma-related hospitalizations after implementing SABA-free asthma management with a maintenance and anti-inflammatory reliever regimen Nannini, L. J. Neumayer, N. S. Brandan, N. Fernández, O. M. Flores, D. M. Eur Clin Respir J Short Communication Overreliance on short-acting β(2)-agonists (SABA) has been a common feature of asthma management globally for at least 30 years. However, given the evidence against the long-term use of SABA, including potentially increased risk of exacerbations, emergency room visits, overall healthcare resource utilization, and mortality, the latest Global Initiative for Asthma report no longer recommends SABA only therapy. Since 2014, we implemented an ICS-containing reliever strategy at our asthma center at the G Baigorria Hospital in Argentina; we only administered budesonide/formoterol via a single inhaler device across the spectrum of asthma severity and completely eliminated the use of SABA therapy. In this article, we compare hospitalization data from our center, previously reported in the EAGLE study (when inhaled corticosteroids plus as-needed SABA was administered) for the years 1999 and 2004 with data from 2017 to 2018 (when budesonide/formoterol in a single inhaler device was administered as maintenance and/or anti-inflammatory reliever therapy [MART/AIR] without any SABA) from our center, to assess the impact of two distinct asthma management strategies on asthma-related hospitalizations. MART/AIR regimens in our SABA-free center reduced asthma hospitalizations from 9 (1999 and 2004) to 1 (2017 and 2018) (Fisher’s exact test, p = 0.031; odds ratio = 0.11; 95% confidence interval [CI] = 0.013–0.98); the hospitalization rate was reduced by 92% (1.47% in 1999 and 2004 to 0.12% in 2017 and 2018). Our data provide preliminary real-world evidence that MART/AIR with budesonide/formoterol simultaneously with SABA elimination across asthma severities is an effective asthma management strategy for reducing asthma-related hospitalizations. Taylor & Francis 2022-08-08 /pmc/articles/PMC9361757/ /pubmed/35959199 http://dx.doi.org/10.1080/20018525.2022.2110706 Text en © 2022 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group. https://creativecommons.org/licenses/by-nc/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial License (http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) ), which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Short Communication
Nannini, L. J.
Neumayer, N. S.
Brandan, N.
Fernández, O. M.
Flores, D. M.
Asthma-related hospitalizations after implementing SABA-free asthma management with a maintenance and anti-inflammatory reliever regimen
title Asthma-related hospitalizations after implementing SABA-free asthma management with a maintenance and anti-inflammatory reliever regimen
title_full Asthma-related hospitalizations after implementing SABA-free asthma management with a maintenance and anti-inflammatory reliever regimen
title_fullStr Asthma-related hospitalizations after implementing SABA-free asthma management with a maintenance and anti-inflammatory reliever regimen
title_full_unstemmed Asthma-related hospitalizations after implementing SABA-free asthma management with a maintenance and anti-inflammatory reliever regimen
title_short Asthma-related hospitalizations after implementing SABA-free asthma management with a maintenance and anti-inflammatory reliever regimen
title_sort asthma-related hospitalizations after implementing saba-free asthma management with a maintenance and anti-inflammatory reliever regimen
topic Short Communication
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9361757/
https://www.ncbi.nlm.nih.gov/pubmed/35959199
http://dx.doi.org/10.1080/20018525.2022.2110706
work_keys_str_mv AT nanninilj asthmarelatedhospitalizationsafterimplementingsabafreeasthmamanagementwithamaintenanceandantiinflammatoryrelieverregimen
AT neumayerns asthmarelatedhospitalizationsafterimplementingsabafreeasthmamanagementwithamaintenanceandantiinflammatoryrelieverregimen
AT brandann asthmarelatedhospitalizationsafterimplementingsabafreeasthmamanagementwithamaintenanceandantiinflammatoryrelieverregimen
AT fernandezom asthmarelatedhospitalizationsafterimplementingsabafreeasthmamanagementwithamaintenanceandantiinflammatoryrelieverregimen
AT floresdm asthmarelatedhospitalizationsafterimplementingsabafreeasthmamanagementwithamaintenanceandantiinflammatoryrelieverregimen